cenderitide

Cenderitide is a novel, engineered chimeric natriuretic peptide developed as a potential treatment for heart failure. It was designed by fusing the full structure of C-type natriuretic peptide (CNP) with the 15-amino acid C-terminus of dendroaspis natriuretic peptide (DNP), resulting in a dual activator of the particulate guanylyl cyclase receptors pGC-A and pGC-B (also known as natriuretic peptide receptor A and natriuretic peptide receptor B). This dual activation aims to combine the renal-enhancing and diuretic properties associated with DNP/pGC-A activation with the antifibrotic effects mediated by CNP/pGC-B activation, while minimizing hypotension. The drug increases cyclic GMP levels in target tissues, leading to beneficial cardiovascular effects such as reduced cardiac fibrosis and improved renal function. Cenderitide has been investigated primarily for use in heart failure patients—especially to prevent re-hospitalization after acute decompensated heart failure—and has also been studied for ST elevation myocardial infarction[1][2][3][4][5][6][7][8].

Other names

chimeric natriuretic peptide